- recruitingPHASE3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
This study looks at the long-term safety of a new medicine, KarXT, for people with schizophrenia whose current treatment isn't working well enough. It's for those who have already started in a previous related study.
United States · Bulgaria · Czechia - recruitingPHASE2
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
This study is testing a new medicine, NBI-1117570, for adults aged 18-55 who are in hospital because of a flare-up of their schizophrenia symptoms. It aims to see if the new medicine helps improve these symptoms compared to a dummy pill.
Bulgaria · United Kingdom - authorisedTherapeutic exploratory (Phase II)
A Phase 2a, Randomized, Participant- and Investigator blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with DSM-5 Schizophrenia (STAR-1)
This study is testing a new medicine, GXV813, for adults in hospital with schizophrenia. Researchers want to see if it's safe, how well people tolerate it, and if it helps with symptoms after six weeks compared to a dummy pill. It's an early-stage study to understand the medicine better.
Bulgaria - authorisedTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)
This study is looking into a new medicine called KarXT for teenagers (aged 13-17) who have schizophrenia. Researchers want to see if KarXT can help improve symptoms and if it is safe to use. Some teens will get KarXT, and others will get a dummy medicine.
Romania - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intramuscular Injection in Healthy Subjects
This study is comparing two medicines for schizophrenia, LY03010 and Xeplion®, to see if they work the same way in the body. It involves healthy volunteers getting a single injection to help us understand how the new medicine is absorbed.
Portugal - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia
This study is testing a new medicine, Valbenazine, for people with schizophrenia. Researchers want to see if it helps improve symptoms when taken alongside other treatments, how safe it is, and if people can tolerate it well.
Romania · Czechia · Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia
This study is looking at a new medicine called Valbenazine for people with schizophrenia. It aims to see if adding Valbenazine to existing treatments helps reduce symptoms and improve daily life over 10 weeks. Some people will get the medicine, others a dummy pill.
Bulgaria · Croatia · Czechia - ongoing, recruitingTherapeutic exploratory (Phase II)
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia
This study is looking at a new medicine called Emraclidine for adults with schizophrenia over 52 weeks. It aims to see if the medicine is safe and if people can take it for a long time without too many problems.
Hungary · Bulgaria - authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
This study is looking at a new version of a medication for schizophrenia. It compares how this new version is handled by the body to an existing medication, to see if they work in a similar way after several doses.
Bulgaria · Croatia · Portugal - ongoing, recruitingHuman Pharmacology (Phase I)- Other
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants with Schizophrenia
This study is looking at a new way to give a medicine called olanzapine, which is used for schizophrenia, to see if it works as well as the usual pills. It's a very early-stage study to check how the body uses the new medicine compared to the old one.
Germany · Spain · France - ongoing, recruitingTherapeutic exploratory (Phase II)
EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680
This study looks at a medicine called Tasmar to see if it can improve thinking skills in people with schizophrenia. Researchers are focusing on individuals with a specific genetic marker (rs4680) to understand how the medicine affects their brain and daily function.
Spain - ongoing, recruitingTherapeutic exploratory (Phase II)
An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia (CIAS)
This study is looking into a new medication called RL-007 to help people with schizophrenia improve their thinking, learning, and memory skills. It's a key step to see if RL-007 is safe and effective.
Poland · Bulgaria · Czechia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
This study is looking into a new medication called KarXT for adults with schizophrenia who aren't getting enough relief from their current treatments. It aims to see if KarXT can help reduce symptoms, compared to a dummy pill, over a 6-week period.
Bulgaria - ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
Netherlands · Croatia · Finland - ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
This study is looking at the long-term safety of a new medicine called KarXT for people with schizophrenia. It's a follow-up to earlier studies, helping us understand how safe it is when used for a longer time, and if there are any side effects.
Bulgaria - ongoing, recruitingTherapeutic exploratory (Phase II)
Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine?
This study looks at whether a medicine called semaglutide (often known as Ozempic) can help people with schizophrenia on certain antipsychotic medicines. Researchers want to see if it can prevent or slow down problems with blood sugar, like pre-diabetes or diabetes, in these patients.
Denmark - recruiting
Energetics and Glutamate in Schizophrenia
This study compares brain activity and chemistry in healthy people and those with schizophrenia. Using special scans, researchers want to see if there are differences in how the brain uses sugar and other chemicals, which could help us understand schizophrenia better.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy Participants
This study is testing a new medicine, CLE-905-AG, for people with schizophrenia. It's a very early-stage trial looking at how safe the medicine is, how well the body handles it, and how much is needed. Healthy volunteers are taking part to help us learn more before it's given to patients.
France